Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Conantokin-G
Overview
Conantokin-G is a 17-amino acid peptide originally isolated from the venom of the cone snail Conus geographus. It acts as a selective antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit, which are implicated in chronic pain, neuropathic pain, and central sensitization.
Mechanism of Action
The peptide contains gamma-carboxyglutamic acid residues that are critical for its activity and metal ion binding. Conantokin-G represents a novel class of non-opioid analgesics targeting glutamatergic neurotransmission.
Research Summary & Key Findings
Preclinical studies have demonstrated analgesic and neuroprotective effects of conantokin-G in rodent models of neuropathic pain, epilepsy, and ischemic injury. The peptide showed promise in early safety and pharmacokinetic studies, but clinical development has been limited. Challenges include synthesis complexity, delivery to the central nervous system, and limited clinical trial data in pain populations.
Clinical Status
Conantokin-G is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Conantokin-G"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Conantokin-G"
Registered interventional and observational studies, including status and phase.
- PubChem: "Conantokin-G"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Pain
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone...
View detailsDifelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing periphera...
View detailsARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the inna...
View detailsPalmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to ti...
View detailsNo lawful pathway today
Conantokin-G is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.